{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"CD25 (sCD25)and CD22 (sCD22) quantify hairy cell leukemia (HCL) tumor burden. Patients with either PR or CR are evaluated for soluble forms of CD25 (sCD25) and soluble CD22 (sCD22). The number of patients with PR or CR who have normalization of sCD25 and sCD22 will be recorded. Normalization is considered \\<3 ng/ml for sCD25, and \\<2 ng/ml for sCD22. Patients will be assessed for normalization of sCD25 and sCD22 for at least 12 months after achieving PR or CR.","groups":[{"description":"30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.","id":"OG000","title":"BL22 Immunotherapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"patients may undergo lymphapheresis before the first and/or later cycles up to 12 months after achieving CR or PR","title":"Percentage of Patients Who Respond Clinically, Who Also Have Normalization in sCD22 or sCD25","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}